> navigate:  
  Academic Programs

Gregory Smallwood, PharmD

Gregory A. Smallwood, PharmD, FCCP

Chair and Associate Professor of Pharmacy Practice

Contact
Ph: 678-407-7342
FX: 678-407-7339
E-mail: gregorysm@pcom.edu

Education

PharmD, University of Georgia College of Pharmacy, 2001
BS (Phr), University of Georgia College of Pharmacy,1979

Narrative

Dr. Smallwood has over 30 years experience as a practicing hospital pharmacist with 15 years as a clinical pharmacy specialist with a liver transplant team. He comes to PCOM School of Pharmacy from the School of Medicine at Emory University. He has published over 40 peer-reviewed articles, has made numerous national and international scientific presentations, is on the editorial board of Annals of Pharmacotherapy, and is a grant reviewer for the country of Qatar.

Dr. Smallwood currently coordinates several courses within the School of Pharmacy. He teaches the Clinical Pharmacy course for P3 students as well as coordinates the Sterile Laboratory associated with this course. He also teaches in several of the integrated therapeutics courses for the P3 students. For the P2 students in the School of Pharmacy he coordinates Pharmacokinetics.

Dr. Smallwood has been an investigator or co-investigator of more than 40 human clinical trials. His research interest includes immunology, transplant, and diabetes with his most recent work being with the Immune Tolerance Network (ITN) using immunosuppressants in treating Type 1 diabetes which is funded by the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH).

Honors/Awards

Elected as a Fellow of the American College of Clinical Pharmacy (ACCP). October 21, 2012 at the 2012 Annual Meeting in Hollywood, Florida.

President Choice Award, Emergence of drug resistance cytomegalovirus following liver transplantation. American Association for the Study of Liver Disease (AASLD) annual meeting. November 12-15, 2005; San Francisco, CA

Recipient of an Award of Excellence in Pharmacy. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic. 3rd International Congress on Immunosuppression. December, 2004 - Manchester Grand Hyatt San Diego, San Diego, CA

President Choice Award, Increased survival in pediatric acute hepatic failure following liver transplantation with early surgical intervention utilizing living donor, partial grafts, and ABO incompatible grafts. American Association for the Study of Liver Disease (AASLD) annual meeting. November 2005; San Francisco, CA

Selected Publications

Heffron TG. Pillen T. Smallwood G. Henry S. Sekar S. Solis D. Casper K. Fasola C. Romero R. Liver re-transplantation in children: the Atlanta experience. Pediatric Transplantation. 14(3):417-25, 2010 May.

Heffron TG, Pillen T, Smallwood G, Rodriguez J, Sekar S, Henry S, Vos M, Casper K, Gupta N, Fasola CG, Romero R. Pediatric liver transplantation for acute liver failure at a single center: a ten-year experience. Pediatric Transplantation; 14:228-232, 2010.

Gregory A. Smallwood, Renee Devine, Carlos Fasola, Andrei Stieber, and Thomas G. Heffron. Does interferon use prior to liver transplant influence hepatitis C outcomes following transplantation? Transplantation. 86(12):1795-1798, 2008 Dec
Nature Reviews Gastroenterology & Hepatology, 6:194, 2009 April

Gregory A. Smallwood. Immunosuppressive strategies to avoid complications: the Achilles’ heel of transplantation. Current Opinion in Organ Transplantation Vol. 11, No. 6; 613-20. 2006

Jenny Bell & Gregory A. Smallwood. Current issues and treatment strategies for female transplant recipients. Graft Vol. 7, No. 4, pg. 233-46, June 2005

GA Smallwood, D. Burns, C Fasola, AC Stieber, TG Heffron. Relationship between immunosuppression and osteoporosis in an outpatient liver transplant clinic Transplant Proceedings, 37, 1910-11, 2005 May

GA Smallwood, L Davis, K Connor, E Martinez, AC Stieber, and TG Heffron Nonresponders of Interferon/Ribavirin Treatment for Recurrent Hepatitis C Following Liver transplantation. Transplantation Proceedings. 35(4): 1476-7, 2003 June

Selected Presentations

Should the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) equation be used to evaluate renal function in the hepatic failure patient awaiting liver transplantation? Gregory Smallwood, B.S., Phr., Pharm.D. ACCP Annual Meeting, Platform Presentation (oral) and Judged to be in the top 8 out of 554 submitted abstracts for the conference; Hollywood, Fl. Pharmacotherapy 2012; 32(10); e179

Is valganciclovir a viable option for cytomegalovirus (CMV) prophylaxis in liver transplantation? Gregory Smallwood, B.S., Pharm.D. 2011 ACCP Annual Meeting, Platform Presentation (oral); Pittsburg, Pa. Pharmacotherapy 2011; 31(10); 386e

Cytomegalovirus infection in the pediatric liver transplant recipient. GA Smallwood, K Casper, T Barnett, T Heffron .Platform Presentation (oral) 2010 ACCP Annual Meeting; Austin, TX. Pharmacotherapy 2010; 30(10); 415e

The evaluation of renal clearance calculations for hepatic failure patients awaiting liver transplantation.G. Smallwood, C. Stearns, T. Heffron. 2008 ACCP Annual Meeting; Platform Presentation (oral); Kentucky International Convention Center; Lexington, KY

Preemptive vs. prophylactic approach to cytomegalovirus in liver transplantation. G. Smallwood, K. Kempton, A. Stieber, C. Fasola, T. Heffron. XXII International Congress of the Transplantation Society. Platform Presentation (oral); Sydney Convention Center Sydney, Australia; Transplantation, July 2008, Vol. 86, 2S; pg 248

Does interferon use prior to liver transplant influence hepatitis C outcomes following transplantation? G. Smallwood, A. Stieber, C. Fasola, T. Heffron. XXII International Congress of the Transplantation Society;Platform Presentation (oral) with award; Sydney Convention Center; Sydney, Australia; Transplantation, July 2008, Vol. 86, 2S; pg 63

Ten year experience with preemptive approach to CMV infection in pediatric liver transplantation. G. Smallwood, T. Pillen, R. Romero, T. Heffron. XXII International Congress of the Transplantation Society.Platform Presentation (oral); Sydney Convention Center; Sydney, Australia; Transplantation, July 2008, Vol. 86, 2S; pg 177

Long term Calcineurin sparing with daclizumab used in an outpatient liver transplant clinic. G. Smallwood, K. Kempton, A. Stieber, C. Fasola, T. Heffron. XXII International Congress of the Transplantation Society.Platform Presentation (oral); Sydney Convention Center; Sydney, Australia; Transplantation, July 2008, Vol. 86, 2S; pg 128

Volunteer & Leadership

Community Advisory Panel (CAP) Member for the PBRN (Practice Based Research Network) of the American College of Clinical Pharmacist (ACCP)

Member of the Institutional Review Board (IRB), Biomedical Committee Emory University, Atlanta, Ga

Frontiers – PRN Representative, American College of Clinical Pharmacist (ACCP)

Planning committee for the Immune Tolerance Network (ITN) sponsored by NIAID entitled: ITN045AI: Multicenter, randomized trial entitled: Inducing Remission in New Onset T1DM with Alefacept (Amevive®).

International Committee member to develop a non-adherence consensus statement in solid organ transplantation for the American Society of Transplantation(AST), American Society of Transplant Surgeons(ASTS), and the International Pediatric Transplant Society(IPTS)

Enhancing Wellness: Lifelong Success for the Transplant Patient website. Health Maintenance Committee, American Society of Transplantation (AST). November 2005

Planning committee member for the Baylor HCV project following liver transplantation sponsored by Baylor Medical Center and Roche

Grants

A Phase II, Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day - Sponsored by Lifecycle Pharma

An Open Label Phase II Extension Study for Patients Completing Study LCP-Tacro 2012 (An Open-Label, Multi-Center Prospective, Conversion Study in Stable Liver Transplant Patients to Compare the Pharmacokinetics of LCP-Tacro Tablets Once-A-Day to Prograf® Capsules Twice-A-Day) – Sponsored by Lifecycle Pharma

“Comparison of mycophenolate mofetil (CellCept®) pharmacokinetics of mycophenolic acid (MPA) to enteric coated mycophenolate sodium (Myfortic®) in stable, long-term liver transplant recipients - Sponsored by F. Hoffmann-La Roche Ltd.

“A randomized, controlled, multicenter study of Thymoglobulin induction therapy with a calcineurin-inhibitor sparing regimen in liver transplant patients.” - Sponsored by SangStat Medical Corporation

Last Updated: 4/17/15